echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Can the old drug suramin sodium cure the sequelae of the new crown?

    Can the old drug suramin sodium cure the sequelae of the new crown?

    • Last Update: 2022-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to foreign media reports, the South African Food and Drug Administration has recently approved a clinical study of the use of suramin sodium in the treatment of new crown sequelae, and patients will be recruited from the first quarter of this year
    .

    The study was filed by a biopharmaceutical company called PaxMedica
    .

    On January 7, 2022, the company announced that PAX-101 (suramin sodium for injection) was approved by the South African Medicines Regulatory Authority (SAHPRA) to study the therapeutic effect of patients with new crown sequelae (LCS, Long Covid Syndrome)
    .

    LCS is a serious multisystem disease that can lead to severe impairment of function in patients
    .

    The Phase 1B study, named PAX-LCS-101, will be a randomized, controlled, double-blind, multi-dose group prospective manner, specifically targeting physical and neuropsychiatric symptoms lasting more than 12 weeks after infection with the new coronavirus
    .

    Diagnosis of LCS is challenging because no specific test is used to confirm the diagnosis
    .

    Although many definitions have been proposed in the medical literature, most researchers define LCS as a syndrome that includes physical and neuropsychiatric symptoms lasting more than 12 weeks without other etiologies
    .

    Symptoms of LCS may vary from patient to patient, but typically include fatigue, short-circuiting of the brain, body aches, headache, shortness of breath, difficulty concentrating, sleep disturbance, orthostatic dizziness, joint and muscle pain, depression and anxiety, and many related symptoms
    .

    The currently observed LCS is highly similar to the symptoms known as Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), including physical fatigue and other similar symptoms
    .

    In addition, both disorders can prevent work or normal activities
    .

    In the extreme case of ME/CFS, according to past data, affected individuals are confined to their homes even if they are not bedridden
    .

    PaxMedica plans to use suramin sodium as a treatment for LCS and ME/CFS
    .

    "People with LCS and ME/CFS have nearly identical physical symptoms and similar pathophysiology related to mitochondrial and purinergic signaling
    .

    Suramin, as a purinergic receptor antagonist, may play a role in addressing Both diseases play an important role in the syndrome,
    "
    commented Robert K.
    Naviaux, MD, co-director of the Center for Mitochondrial and Metabolic Diseases at the University of California at San Diego School of Medicine
    .

    A clinical trial is planned to investigate the safety, tolerability, efficacy and in vivo dynamics of the drug in two doses of suramin sodium (5mg/kg and 10mg/kg) in adults 18 years and older with LCS
    .

    There is clearly an unmet medical need for LCS, but there are currently no approved drugs to treat the disease
    .

    There is a growing consensus in the scientific and medical communities that more research is needed on the causes of LCS and potentially related ME/CFS
    .

    PAX-101 Suramin sodium for injection in the treatment of autism spectrum disorder (ASD, Autism Spectrum Disorder) is in Phase II
    .

    Additionally, the company is developing PAX-102 as a suramin sodium nasal drop for ASD and other neurological disorders
    .

    PaxMedica is a clinical-stage pharmaceutical company leading the development of PAX-101 to advance its use in ASD, ME/CFS, LCS and Fragile X-related tremor/ataxia syndrome
    .

    Although ASD is common in many communities, no FDA-approved treatment for its core symptoms exists
    .

    PaxMedica's most advanced clinical treatment, PAX-101, is currently being evaluated in clinical trials to support the treatment of core and related symptoms in children with ASD
    .

    Naviaux studies using suramin sodium for the treatment of autism for decades have achieved statistical significance in two animal models of ASD and a small clinical trial [1,2,3]
    .

    In order to further reveal the pharmacodynamic mechanism, Naviaux also measured the time series of various biomarkers [4]
    .

    Naviaux believes that purinergic antagonist therapy (typically suramin sodium) is the underlying logic to solve a class of neurological diseases (typically ASD), which is why he believes that suramin sodium has the potential to treat the sequelae of the new crown
    .

    References [1]Naviaux, Robert K.
    , et al.
    "Antipurinergic therapy corrects the autism-like features in the poly (IC) mouse model.
    " PloS one 8.
    3 (2013): e57380.
    [2]Naviaux, Jane C.
    , et al.
    "Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.
    " Molecular autism 6.
    1 (2015): 1-20.
    [3]Naviaux, Robert K.
    , et al.
    "Low ‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial.
    " Annals of clinical and translational neurology 4.
    7 (2017): 491-505.
    [4]Zolkipli-Cunningham, Zarazuela, et al.
    "Metabolic and behavioral features of acute hyperpurinergia and the maternal immune activation mouse model of autism spectrum disorder.
    " PloS one 16.
    3 (2021): e0248771
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.